- With 12 units, it is highly competitive and the largest of its kind in Korea

- Foundation for entry to the global market, including the USA, Europe and Japan




The largest advanced raw material medicine production base in Korea has been born. 
Daewoong Pharmaceutical Co., Ltd (President Lee Jong Wook) held a completion ceremony for the 3rd plant (Balan new plant), which includes a cGMP advanced production facility that meets the international medicine production standard, at ‘Balan local industrial complex’ in Hyanganm-eup, Hwaseong-si, Gyeonggi on the 20th. Over 150 guests attended the ceremony, including President Lee Jong Wook, Director of Medicine Safety in KFDA, President of Kyoasho Tosiyuki Shuto, and directors and representatives of overseas customers. 

At the ceremony, President Lee said "the 3rd plant reinforces our competitiveness, allowing us to supply the best quality products that meet cGMP standards through quality management. This will be a stepping stone that will help Daewoong Bio to develop as a global company that exportsraw material medicine to advanced countries such as the USA, Europe and Japan." 

The project started last February with a 65 billion won investment, and was completed after 14 months of construction. The new factory will be operated starting in May. With 12 units in a 14,929 ㎡ building area on a 46,892㎡ site, including a general medicine unit and the carbapenem unit, it is the largest raw material medicine plant in Korea. It is built to meet cGMP (USA good manufacturing practices) standards, and is a low carbon green plant. Closed system, cGMP standard air-conditioning system, the only exclusive penem production unit in Korea, building arrangement considering wind effect, BMS (building management system) for 24-hour control of pressure, temperature and humidity have been introduced to ensure the production of high quality medicine.

The complex can produce 200 tons of medicine annually, including UDCA (Product name: Ursa), general medicine, carbapenem asepsis products and brand new products. It also performs consignment production from Japan and the USA. For UDCA, it is expected to more than double current production levels, from 70 tons to 150 tons. 

A spokesperson for Daewoong Pharmaceutical said that "when the production capacity from the 1st, 2nd and 3rd plants is combined, it shall be the largest facility, and we plan to increase sales to 400 billion won in 2015 from the current level of 120 billion won.